JASPER: Phase 2 trial of first-line niraparib plus pembrolizumab in patients with advanced non-small cell lung cancer.

Ramalingam, Suresh S; Thara, Eddie; Awad, Mark M; Dowlati, Afshin; Haque, Basir; Stinchcombe, Thomas E; Dy, Grace K; Spigel, David R; Lu, Sharon; Iyer Singh, Nithya; Tang, Yongqiang; Teslenko, Iryna; Iannotti, Nicholas

Ramalingam, Suresh S; Thara, Eddie; Awad, Mark M; Dowlati, Afshin; Haque, Basir; Stinchcombe, Thomas E; Dy, Grace K; Spigel, David R; Lu, Sharon; Iyer Singh, Nithya; Tang, Yongqiang; Teslenko, Iryna; Iannotti, Nicholas.

Afiliação

Ramalingam SS; Emory University, Winship Cancer Institute, Atlanta, Georgia.
Thara E; Oncology Institute of Hope and Innovation, Los Angeles, California.
Awad MM; Dana-Farber Cancer Institute, Boston, Massachusetts.
Dowlati A; University Hospitals Seidman Cancer Center and Case Western Reserve University, Cleveland, Ohio.
Haque B; Kadlec Clinic Hematology and Oncology, Kennewick, Washington.
Stinchcombe TE; Duke Cancer Institute, Duke University School of Medicine, Durham, North Carolina.
Dy GK; Roswell Park Comprehensive Cancer Center, Buffalo, New York.
Spigel DR; Sarah Cannon Research Institute/Tennessee Oncology, Nashville, Tennessee.
Lu S; GlaxoSmithKline, Waltham, Massachusetts.
Iyer Singh N; GlaxoSmithKline, Waltham, Massachusetts.
Tang Y; GlaxoSmithKline, Waltham, Massachusetts.
Teslenko I; GlaxoSmithKline, Waltham, Massachusetts.
Iannotti N; Hematology Oncology Associates of the Treasure Coast, Port St. Lucie, Florida.

Cancer ; 128(1): 65-74, 2022 Jan 01.

Article em En | MEDLINE | ID: mdl-34478166

Assuntos

Anticorpos Monoclonais Humanizados; Carcinoma Pulmonar de Células não Pequenas; Indazóis; Neoplasias Pulmonares; Piperidinas; Anticorpos Monoclonais Humanizados/efeitos adversos; Protocolos de Quimioterapia Combinada Antineoplásica/efeitos adversos; Carcinoma Pulmonar de Células não Pequenas/tratamento farmacológico; Carcinoma Pulmonar de Células não Pequenas/patologia; Humanos; Indazóis/efeitos adversos; Neoplasias Pulmonares/tratamento farmacológico; Neoplasias Pulmonares/patologia; Piperidinas/efeitos adversos; Inibidores de Poli(ADP-Ribose) Polimerases/efeitos adversos

Palavras-chave

clinical study; combination drug therapy; lung neoplasms; niraparib; non-small cell lung carcinoma; pembrolizumab; poly(ADP-ribose) polymerase inhibitors

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Piperidinas / Carcinoma Pulmonar de Células não Pequenas / Anticorpos Monoclonais Humanizados / Indazóis / Neoplasias Pulmonares Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google